- SID Score
- 6.8/10
- Fair value
- $509.31
- Generated
- Aug 26, 2026
- Model
- claude-haiku-4-5-20251001
Bristol-Myers Squibb's Preferred Convertible 2 (BMYMP) is trading at $400.00 with a substantial market capitalization of $1.82 trillion, positioning it as a major player in the healthcare sector. The stock presents an attractive fair value estimate of $509.31, suggesting 27.3% upside potential according to valuation models. With a Buy consensus from analysts and a moderate SID Score of 6.8/10, the security warrants consideration for income-focused and value-oriented investors seeking exposure to a large-cap pharmaceutical company. However, the extremely low dividend yield of 0.05% indicates this is primarily a capital appreciation play rather than a traditional income vehicle.
The company's P/E ratio of 17.28 suggests moderate valuation relative to earnings, which is reasonable for a mature pharmaceutical firm with substantial market presence. Factor analysis reveals mixed fundamental health: Dividends earn a B grade, Profitability rates a C, and Growth receives a C rating, indicating the company maintains acceptable operational performance without exceptional expansion prospects. The concerning D grade for Value suggests the stock may be fairly priced to slightly expensive at current levels, despite the 27.3% upside to fair value, which implies some analytical disagreement on true intrinsic worth. The lack of recent financial data in the analysis limits deeper fundamental assessment of cash flow generation, debt levels, and balance sheet strength.
Unfortunately, critical technical indicators including RSI(14), 50-Day Moving Average, and 200-Day Moving Average are not available for analysis, preventing assessment of momentum, trend direction, and support/resistance levels. Without these standard technical metrics, investors cannot determine whether the stock is oversold, overbought, or trading within established trend channels. The absence of moving average data is particularly problematic for convertible preferreds, which often exhibit distinct technical patterns that guide entry and exit timing. Additional technical analysis would be necessary to validate whether current price levels represent attractive accumulation opportunities or should trigger caution.
Analyst & Insider Sentiment
Analyst consensus maintains a Buy rating, though the average price target is not provided, limiting insight into the magnitude of recommended price appreciation beyond the internal fair value estimate of $509.31. Recent insider activity presents a mixed signal, with Short Bartie Wendy executing significant transactions totaling 20,121 shares sold followed by 15,957 shares purchased in June 2026, suggesting portfolio rebalancing rather than conviction-based directional betting. Adam Lenkowsky's consecutive stock sales in May 2026 totaling 21,081 shares without corresponding purchases indicate potential insider concern about valuation or capital reallocation priorities. The neutral news sentiment and lack of recent major news developments suggest the market has absorbed previous catalysts and awaits new information to drive directional movement.
Convertible preferred shares carry structural risks including call risk (issuer can force conversion), interest rate sensitivity, and credit risk specific to Bristol-Myers Squibb's financial stability, though these details are not explicitly disclosed in available data. The extremely tight dividend yield of 0.05% leaves minimal margin of safety for income investors, making capital appreciation dependent upon company stock price performance and potential conversion scenarios. The concerning insider selling activity, particularly Adam Lenkowsky's one-sided sales pattern, may signal executive concern regarding valuation sustainability or future earnings prospects, warranting investor caution. Additionally, the healthcare sector faces regulatory, patent cliff, and competitive pressures that could impact the parent company's financial performance and the preferreds' underlying equity value.
BMYMP represents a moderate-risk opportunity for growth-oriented investors seeking equity-like upside exposure through a preferred security vehicle, with the 27.3% fair value differential providing meaningful return potential if valuation models prove accurate. The B-rated dividend profile combined with the Buy analyst consensus supports accumulation for patient capital, though the minimal current yield limits appeal for immediate income generation. However, the mixed insider sentiment evidenced by notable executive selling, combined with soft fundamental grades in Value and Growth, suggests investors should limit position sizes and wait for more compelling technical confirmation before aggressively accumulating shares. Conservative investors should consider this security only as a satellite position within a diversified healthcare allocation, with entry discipline guided by improved technical signals and resolution of recent insider activity concerns.
